Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUMELEP: Durvalumab + Tremelimumab peri-procedural therapy with electroporation ablation in BCLC A hepatocellular carcinoma
2022-003561-38Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Local recurrence-free survival at 1 year. Started Jan 2023; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-003561-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003561-38.